Panbela Therapeutics Inc (OTCPK:PBLA)

$ 0.3621 0 (0%) Market Cap: 1.76 Mil Enterprise Value: 5.69 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 30/100

Q1 2024 Panbela Therapeutics Inc Earnings Call Transcript
May 15, 2024

$0.4 (-9.25%)

Earnings
Q4 2023 Panbela Therapeutics Inc Earnings Call Transcript
Mar 26, 2024

$0.64

Earnings
Q3 2023 Panbela Therapeutics Inc Earnings Call Transcript
Nov 09, 2023

$11.64 (-13.13%)

Earnings
Panbela Therapeutics Inc at LD Micro Main Event XVI Conference Transcript
Oct 04, 2023
Q2 2023 Panbela Therapeutics Inc Earnings Call Transcript
Aug 10, 2023

$33.8 (-2.31%)

Earnings
Panbela Therapeutics Inc Annual Shareholders Meeting Transcript
May 25, 2023
Q1 2023 Panbela Therapeutics Inc Earnings Call Transcript
May 04, 2023

$270 (-7.27%)

Earnings
Q4 2022 Panbela Therapeutics Inc Earnings Call Transcript
Mar 16, 2023

$396 (-0.74%)

Earnings
Panbela Therapeutics Inc Extraordinary Shareholders Meeting Transcript
Nov 29, 2022
Q3 2022 Panbela Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

$2659.2 (+0.64%)

Earnings
Q2 2022 Panbela Therapeutics Inc Earnings Call Transcript
Aug 15, 2022

$28559.98 (-7.71%)

Earnings
Q1 2022 Panbela Therapeutics Inc Earnings Call Transcript
May 12, 2022

$38563.17 (-0.20%)

Earnings
Q3 2021 Panbela Therapeutics Inc Earnings Call Transcript
Nov 10, 2021

$48479.96 (-3.35%)

Earnings
Q2 2021 Panbela Therapeutics Inc Earnings Call Transcript
Aug 11, 2021

$57599.95 (-2.04%)

Earnings
Q1 2021 Panbela Therapeutics Inc Earnings Call Transcript
May 12, 2021

$95999.92 (-3.85%)

Earnings

Panbela Therapeutics Inc at LD Micro Main Event XVI Conference Transcript

Oct 04, 2023 / 10:30PM GMT

Release Date Price: $24 (+2.56%)

Transcript

Unidentified Participant

Okay, I'm excited to bring to you our next presentation. So please give a warm welcome to CEO, Dr. Jennifer Simpson of Panbela Therapeutics.

Jennifer Simpson

Panbela Therapeutics, Inc. - President & CEO

Thank you. Good afternoon, everyone. This presentation will contain forward-looking statements, so I do encourage you to look at the documents filed with the SEC.

So Panbela Therapeutics is a company that focuses on polyamines, and polyamines are key regulators of normal biology, and they are altered in many disease states. We have a combined pipeline that spans from preclinical through Phase III registration programs, which translates to approximately a $5 billion aggregate market potential across the lead indications. We have strategic synergies and partnerships, which help to fund many of the programs.

The management team is highly experienced. We have over 10 FDA approvals under our belt and decades of pharma experience, and this really positions the company well as we continue to execute on our clinical development

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.